SD
Shubham Dattatray Walunj
About Shubham Dattatray Walunj
Data last updated:
Shubham Dattatray Walunj is a Designated Partner at Reviveme Technologies Llp (since 2026) and Designated Partner at Zenvexa Pharmaceuticals Llp (since 2025). The companies operate in Pharma.
Current companies
| Company | Designation | Appointment | Founded | Revenue | Status |
|---|---|---|---|---|---|
 Reviveme Technologies Llp ADA-3474 | Designated Partner | 21 Jul 2026 | 2026 | Active | |
| Zenvexa Pharmaceuticals Llp ACT-0179 | Designated Partner | 27 Nov 2025 | 2025 | Active |
Board colleagues of Shubham Dattatray Walunj
| Name | DIN | Company | Designation |
|---|---|---|---|
| Aman Suresh Tharayil | 11841313 | Reviveme Technologies Llp | Designated Partner |
| Soham Sunil Mhatre | 11398546 | Reviveme Technologies Llp , Zenvexa Pharmaceuticals Llp | Designated Partner |
| Soumen Shayam Maity | Reviveme Technologies Llp | Partner | |
| Vijay Arun Khendke | 11398547 | Zenvexa Pharmaceuticals Llp | Designated Partner |
Directorship timeline
Open interactive timeline →Shareholding and investment profile for Shubham Dattatray Walunj
Company-level share counts, filed values, and quarterly changes require authenticated premium access.
- Company-level holdings
- Filed share counts
- Reported values
- Quarterly changes
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Shubham Dattatray Walunj
Shubham Dattatray Walunj currently holds 2 directorships: Reviveme Technologies Llp (Designated Partner, since 21 Jul 2026); Zenvexa Pharmaceuticals Llp (Designated Partner, since 27 Nov 2025).
Shubham Dattatray Walunj was first appointed on 27 Nov 2025 as Designated Partner at Zenvexa Pharmaceuticals Llp. The most recent appointment on record is 21 Jul 2026 at Reviveme Technologies Llp.
The current boards of Shubham Dattatray Walunj's companies include Aman Suresh Tharayil (Reviveme Technologies Llp), Soham Sunil Mhatre (Reviveme Technologies Llp), Soumen Shayam Maity (Reviveme Technologies Llp), Vijay Arun Khendke (Zenvexa Pharmaceuticals Llp).